INSTRUCTIONS FOR USE

Anti-Rubella Virus IgM

EN

REF **9Z9801M**
SM9Z9801M

IVD

Rx Only

$\sum$ 96

INTENDED USE

The Anti-Rubella Virus IgM is designed for the qualitative detection of IgM antibodies to the rubella virus in human serum. The assay is intended to be used to evaluate serologic evidence of active or recent infection with rubella virus and is for *In Vitro* diagnostic use.

SIGNIFICANCE AND BACKGROUND

Rubella is a mild, contagious viral infection that occurs primarily in children and young adults (1, 2). Research shows that a main characteristic of rubella is an erythematosus, maculopapular rash that lasts two or three days. However, greater than 50% of rubella infections are clinically unapparent (2). Other symptoms of rubella may include low-grade fever, mild upper respiratory symptoms, and sub occipital lymphadenopathy. Transient arthralgia and arthritis are common symptoms in young adults, but more severe complications, such as encephalitis or thrombocytopenic purpura, are very uncommon (1).

Although rubella infection in a child or adult is usually benign and self-limiting, infection of the fetus during the first trimester may cause spontaneous abortion, stillbirth, or congenital birth defects (4). Infants infected in-utero may be born with obvious birth defects or, more commonly, appear normal and either remain normal or develop later complications (1, 2).

Health care professionals and scientists recognize and categorize congenital rubella syndrome by the following symptoms: congenital heart disease, cataracts, neurosensory deafness, mental retardation, and intrauterine growth retardation (1, 4). Following an epidemic of rubella in 1964, scientists recognized other clinical manifestations of congenital rubella, and included neonatal thrombocytopenic purpura, hepatitis, bone lesions, and meningoencephalitis (3). In addition, diabetes mellitus and progressive rubella panencephalitis are late-emerging manifestations of congenital rubella infection that have recently been recognized (1).

Rubella is endemic worldwide (2). In countries without vaccination programs, 10-25% of women of childbearing age are seronegative and susceptible to infection (2). Extensive vaccination programs in the United States and the United Kingdom have greatly reduced the incidence of congenital rubella syndrome (2, 5). The United States reports fewer than 10 cases per year.

The presence of circulating maternal antibody indicates immunity to rubella and virtually excludes the possibility of transmission of rubella to the fetus (2, 5, and 6). If acquisition of rubella occurs during pregnancy, particularly during the first trimester, the fetus may be at risk of becoming infected (1). Acute rubella infection can be confirmed by simultaneously testing paired acute and convalescent sera and looking for seroconversion or a fourfold rise in titer, or by the presence of rubella specific IgM (6). The presence of rubella specific IgM in the neonate or the persistence of a high titer of IgG antibody for longer than expected for passively acquired antibody (6 months) confirms a diagnosis of congenital rubella (6).

Hemagglutination inhibition (HAI), the first widely used technique for detection of rubella antibody, has been the reference standard against which newer methods are measured (7). However, the HAI test is labor intensive and difficult to perform since serum samples must be pretreated to remove b-lipoprotein (6, 8). Research shows ELISA (enzyme-linked immunosorbent assay) testing to be a sensitive and reliable procedure for detection of antibodies to rubella (7, 8, and 9). ELISA is less cumbersome than HAI and more applicable to screening large numbers of samples, since determinations use a single serum dilution that does not require pretreatment. In addition, it is possible to correlate ELISA results, based on an objective absorbency reading, with HAI titers (7, 8).

High affinity IgG antibodies to rubella virus, if present in a sample, may interfere with the detection of IgM specific antibody (10, 11). High affinity IgG antibody may preferentially bind to rubella antigen leading to false negative IgM results (10). Also, rheumatoid factor, if present along with antigen specific IgG, may bind to the IgG causing false positive IgM results (11). Remove IgG from the sample using several different methods before testing for IgM to eliminate both of the above problems. These include sucrose density gradient centrifugation (9), ion exchange chromatography (12), and precipitation of IgG with anti-human IgG serum (13).

sebia
The new language of life

PRINCIPLE OF THE ASSAY

The Anti-Rubella Virus IgM is designed to detect IgM class antibodies to Rubella virus in human sera. Creation of the sensitized wells of the plastic microwell strips occurred using passive adsorption with Rubella antigen. The test procedure involves three incubation steps:

1. Test sera are diluted with the Sample Diluent provided. The Sample Diluent contains antihuman IgG that precipitates and removes IgG and rheumatoid factor from the sample leaving IgM free to react with the immobilized antigen. During sample incubation, any antigen specific IgM antibody in the sample will bind to the immobilized antigen. The plate is washed to remove unbound antibody and other serum components.

2. Peroxidase Conjugated goat anti-human IgM is added to the wells and the plate is incubated. The Conjugate will react with IgM antibody immobilized on the solid phase in step 1. The wells are washed to remove unbound Conjugate.

3. The microwells containing immobilized peroxidase Conjugate are incubated with peroxidase Substrate Solution. Hydrolysis of the Substrate by peroxidase produces a color change. After a period of time the reaction is stopped and the color intensity of the solution is measured photometrically. The color intensity of the solution depends upon the antibody concentration in the original test sample.

TEST SYSTEM COMPONENTS

Materials Provided:

Each Test System contains the following components in sufficient quantities to perform the number of tests indicated on the packaging label. **NOTE:** The following components contain Sodium Azide as a preservative at a concentration of <0.1% (w/v): Controls, Calibrator, and Sample Diluent.

| Kit Component	Quantity $\sum 96$	Description
PLATE	1	Plate: 96 wells configured in twelve, 1x8-well, strips coated with Rubella virus antigen. The strips are packaged in a strip holder and sealed in an envelope with desiccant.
CONJ	1	Conjugate: Conjugated (horseradish peroxidase) goat anti-human IgM (μ chain specific). 15mL, white-capped bottle. Ready to use.
CTRL +	1	Positive Control (Human Serum): 0.35mL, red-capped vial. 21X concentrate.
CAL	1	Calibrator (Human Serum): 0.5mL, blue-capped vial. 21X concentrate.
CTRL –	1	Negative Control (Human Serum): 0.35mL, green-capped vial. 21X concentrate.
DIL SPE	1	Sample Diluent: 30mL, green-capped, bottle containing Tween-20, bovine serum albumin and phosphate-buffered-saline and goat anti-human IgG (y-chain specific). Purple solution. Ready to use.
SOLN TMB	1	TMB: 15mL, amber-capped, amber bottle containing 3, 3', 5, 5' - tetramethylbenzidine (TMB). Ready to use.
SOLN STOP	1	Stop Solution: 15mL, red-capped bottle containing 1M H_2SO_4, 0.7M HCl. Ready to use.
WASH 10X	1	Wash Buffer Concentrate (10X): Dilute 1 part concentrate + 9 parts deionized or distilled water. 100mL, clear-capped bottle containing a 10X concentrated phosphate-buffered-saline and Tween-20 solution (blue solution). **NOTE: 1X solution will have a pH of 7.2 ± 0.2.**

NOTE: The following components are not Test System Lot Number dependent and may be used interchangeably with the ZEUS ELISA Test Systems: TMB, Stop Solution, and Wash Buffer.

MATERIALS REQUIRED BUT NOT PROVIDED

1. ELISA microwell reader capable of reading at a wavelength of 450nm. **NOTE: Use of a single (450nm), or dual (450/620 - 650nm), wavelength reader is acceptable. Dual wavelength is preferred, as the additional reference filter has been determined to reduce potential interference from anomalies that may absorb light.**

2. Pipettes capable of accurately delivering 10 - 200μL.

sebia
The new language of life

3. Multichannel pipette capable of accurately delivering 50 - 200μL.
4. Reagent reservoirs for multichannel pipettes.
5. Wash bottle or microwell washing system.
6. Distilled or deionized water.
7. One-liter graduated cylinder.
8. Serological pipettes.
9. Disposable pipette tips.
10. Paper towels.
11. Laboratory timer to monitor incubation steps.
12. Disposal basin and disinfectant (i.e., 10% household bleach - 0.5% sodium hypochlorite).

STORAGE CONDITIONS

2°C ⌐8°C	Coated Microwell Strips: Immediately reseal extra strips with desiccant and return to proper storage. After opening, strips are stable for 60 days, as long as the indicator strips on the desiccant pouch remain blue.
	Conjugate – DO NOT FREEZE.
	Unopened Kit, Calibrator, Positive Control, Negative Control, TMB, Sample Diluent.
2°C ⌐25°C	Stop Solution: 2 – 25 °C Wash Buffer (1X) : 20 - 25°C for up to 7 days, 2 - 8°C for 30 days Wash Buffer (10X): 2 - 25°C

PRECAUTIONS

1. For *In Vitro* diagnostic use.
2. Follow normal precautions exercised in handling laboratory reagents. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing, gloves, and eye/face protection. Do not breathe vapor. Dispose of waste observing all local, state, and federal laws.
3. The wells of the ELISA plate do not contain viable organisms. However, consider the strips **potentially biohazardous materials** and handle accordingly.
4. The Controls are **potentially biohazardous materials**. Source materials from which these products were derived were found negative for HIV-1 antigen, HBsAg and for antibodies against HCV and HIV by approved test methods. However, since no test method can offer complete assurance that infectious agents are absent, handle these products at the Biosafety Level 2 as recommended for any potentially infectious human serum or blood specimen in the Centers for Disease Control/National Institutes of Health manual "Biosafety in Microbiological and Biomedical Laboratories": Current Edition; and OSHA's Standard for Bloodborne Pathogens (16).
5. Adherence to the specified time and temperature of incubations is essential for accurate results. **All reagents must be allowed to reach room temperature (20 - 25°C) before starting the assay**. Return unused reagents to refrigerated temperature immediately after use.
6. Improper washing could cause false positive or false negative results. Be sure to minimize the amount of any residual wash solution; (e.g., by blotting or aspiration) before adding Conjugate or Substrate. Do not allow the wells to dry out between incubations.
7. The Sample Diluent, Controls, and Calibrator contain Sodium Azide at a concentration of <0.1% (w/v). Sodium Azide has been reported to form lead or copper azides in laboratory plumbing which may cause explosions upon hammering. To prevent, rinse sink thoroughly with water after disposing of solution containing Sodium Azide.
8. The Stop Solution is TOXIC if inhaled, has contact with skin or if swallowed. It can cause burns. In case of accident or ill feelings, seek medical advice immediately.
9. The TMB Solution is HARMFUL. It is irritating to eyes, respiratory system and skin.
10. The Wash Buffer concentrate is an IRRITANT. It is irritating to eyes, respiratory system and skin.
11. Wipe the bottom of the plate free of residual liquid and/or fingerprints that can alter optical density (OD) readings.
12. Dilution or adulteration of these reagents may generate erroneous results.
13. Do not use reagents from other sources or manufacturers.
14. TMB Solution should be colorless, very pale yellow, very pale green, or very pale blue when used. Contamination of the TMB with Conjugate or other oxidants will cause the solution to change color prematurely. Do not use the TMB if it is noticeably blue in color.
15. Never pipette by mouth. Avoid contact of reagents and patient specimens with skin and mucous membranes.
16. Avoid microbial contamination of reagents. Incorrect results may occur.

sebia
The new language of life

17. Cross contamination of reagents and/or samples could cause erroneous results.
18. Reusable glassware must be washed and thoroughly rinsed free of all detergents.
19. Avoid splashing or generation of aerosols.
20. Do not expose reagents to strong light during storage or incubation.
21. Allowing the microwell strips and holder to equilibrate to room temperature prior to opening the protective envelope will protect the wells from condensation.
22. Collect the wash solution in a disposal basin. Treat the waste solution with disinfectant (i.e.: 10% household bleach - 0.5% Sodium Hypochlorite). Avoid exposure of reagents to bleach fumes.
23. Caution: Neutralize any liquid waste at an acidic pH before adding to a bleach solution.
24. Do not use ELISA plate if the indicator strip on the desiccant pouch has turned from blue to pink.
25. Do not allow the Conjugate to come in contact with containers or instruments that may have previously contained a solution utilizing Sodium Azide as a preservative. Residual amounts of Sodium Azide may destroy the Conjugate's enzymatic activity.
26. Do not expose any of the reactive reagents to bleach-containing solutions or to any strong odors from bleach-containing solutions. Trace amounts of bleach (sodium hypochlorite) may destroy the biological activity of many of the reactive reagents within this Test System.

SPECIMEN COLLECTION

1. ZEUS Scientific recommends that the user carry out specimen collection in accordance with CLSI document M29: Protection of Laboratory Workers from Infectious Disease (Current Edition).
2. No known test method can offer complete assurance that human blood samples will not transmit infection. Therefore, consider all blood derivatives potentially infectious.
3. Use only freshly drawn and properly refrigerated sera obtained by approved aseptic venipuncture procedures in this assay (14). Do not use if there are any added anticoagulants or preservatives. Avoid using hemolyzed, lipemic, or bacterially contaminated sera.
4. Store sample at room temperature for no longer than 8 hours. If testing is not performed within 8 hours, sera may be stored between 2 - 8°C, for no longer than 48 hours. If a delay in testing is anticipated, store test sera at −20°C or lower. Avoid multiple freeze/thaw cycles which may cause loss of antibody activity and give erroneous results. It is the responsibility of the individual laboratory to use all available references and/or its own studies to determine stability criteria for its laboratory (17).

ASSAY PROCEDURE

1. Remove the individual components from storage and allow them to warm to room temperature (20 - 25°C).
2. Determine the number of microwells needed. Allow for six Control/Calibrator determinations (one Reagent Blank, one Negative Control, three Calibrators and one Positive Control) per run. Run a Reagent Blank on each assay. Check software and reader requirements for the correct Controls/Calibrator configurations. Return unused strips to the resealable pouch with desiccant, seal, and return to storage between 2 - 8°C.

EXAMPLE PLATE SET-UP		
	1	2
A	Blank	Patient 3
B	Negative Control	Patient 4
C	Calibrator	Etc.
D	Calibrator	
E	Calibrator	
F	Positive Control	
G	Patient 1	
H	Patient 2	

3. Prepare a 1:21 dilution (e.g.: 10µL of serum + 200µL of Sample Diluent) of the Negative Control, Calibrator, Positive Control, and each patient serum.
4. To individual wells, add 100µL of each diluted Control, Calibrator and patient specimen. Ensure that the samples are properly mixed. Use a different pipette tip for each sample.
5. Add 100µL of Sample Diluent to well A1 as a Reagent Blank. Check software and reader requirements for the correct Reagent Blank well configuration.
6. Incubate the plate at room temperature (20 - 25°C) for 25 ± 5 minutes.
7. Wash the microwell strips 5 times.
   a. **Manual Wash Procedure**:
      1. Vigorously shake out the liquid from the wells.
      2. Fill each microwell with Wash Buffer. Make sure no air bubbles are trapped in the wells.

sebia
The new language of life

3. Repeat steps 1. and 2. for a total of 5 washes.
4. Shake out the wash solution from all the wells. Invert the plate over a paper towel and tap firmly to remove any residual wash solution from the wells. Visually inspect the plate to ensure that no residual wash solution remains. Collect wash solution in a disposable basin and treat with disinfectant at the end of the day's run.

   b. **Automated Wash Procedure**:

   If using an automated microwell wash system, set the dispensing volume to 300 - 350µL/well. Set the wash cycle for 5 washes with no delay between washes. If necessary, the microwell plate may be removed from the washer, inverted over a paper towel and tapped firmly to remove any residual wash solution from the microwells.

8. Add 100µL of the Conjugate to each well, including the Reagent Blank well, at the same rate and in the same order as the specimens.
9. Incubate the plate at room temperature (20 - 25°C) for 25 ± 5 minutes.
10. Wash the microwells by following the procedure as described in step 7.
11. Add 100µL of TMB to each well, including the Reagent Blank well, at the same rate and in the same order as the specimens.
12. Incubate the plate at room temperature (20 - 25°C) for 10 - 15 minutes.
13. Stop the reaction by adding 50µL of Stop Solution to each well, including the Reagent Blank well, at the same rate and in the same order as the TMB. Positive samples will turn from blue to yellow. After adding the Stop Solution, tap the plate several times to ensure that the samples are thoroughly mixed.
14. Set the microwell reader to read at a wavelength of 450nm and measure the optical density (OD) of each well against the Reagent Blank. Read the plate within 30 minutes of the addition of the Stop Solution.

ABBREVIATED TEST PROCEDURE

1. Dilute Serum 1:21.
2. Add diluted sample to microwell - 100µL/well.
3. ⟶ *Incubate 25 ± 5 minutes.*
4. Wash.
5. Add Conjugate- 100µL/well.
6. ⟶ *Incubate 25 ± 5 minutes.*
7. Wash.
8. Add TMB- 100µL/well.
9. ⟶ *Incubate 10 - 15 minutes.*
10. Add Stop Solution - 50µL/well - Mix.
11. READ within 30 minutes.

QUALITY CONTROL

1. Each time the assay is performed, the Calibrator must be run in triplicate. A Reagent Blank, Negative Control, and Positive Control must also be included.
2. Calculate the mean of the three Calibrator wells. If any of the three values differ by more than 15% from the mean, discard that value and calculate the mean using the remaining two wells.
3. The mean OD value for the Calibrator, Positive Control, and Negative Control should fall within the following ranges:

	OD Range
Negative Control	≤0.250
Calibrator	≥0.300
Positive Control	≥0.500

   a. The OD of the Negative Control divided by the mean OD of the Calibrator should be ≤0.9.
   b. The OD of the Positive Control divided by the mean OD of the Calibrator should be ≥1.25.
   c. If the above conditions are not met the test should be considered invalid and should be repeated.
4. The Positive Control and Negative Control are intended to monitor for substantial reagent failure, but will not ensure precision at the assay Cutoff.
5. Additional Controls may be tested according to guidelines or requirements of local, state, and/or federal regulations or accrediting organizations.
6. Refer to CLSI document C24: Statistical Quality Control for Quantitative Measurement Procedures for guidance on appropriate QC practices.

sebia
The new language of life

INTERPRETATION OF RESULTS

1. **Calculations:**
   a. *Correction Factor*: The manufacturer determined a Cutoff OD Value for positive samples and correlated it to the Calibrator. The Correction Factor (CF) allows for the determination of the Cutoff Value for positive samples. It will also correct for slight day-to-day variations in test results. The Correction Factor is determined for each lot of components and is printed on the Component Label located in the Test System box.
   b. *Cutoff OD Value*: To obtain the Cutoff OD Value, multiply the CF by the mean OD of the Calibrator determined above.
   (CF x Mean OD of Calibrator = Cutoff OD Value)
   c. *Index Values/OD Ratios*: Calculate the Index Value/OD Ratio for each specimen by dividing its OD Value by the Cutoff OD from step b.

Example:			
Mean OD of Calibrator	=	0.793	
Correction Factor (CF)	=	0.25	
Cutoff OD	=	0.793 x 0.25 = 0.198	
Unknown Specimen OD	=	0.432	
Specimen Index Value/OD Ratio	=	0.432/0.198 = 2.18	

2. **Interpretations:** Index Values/OD Ratios are interpreted as follows.

	Index Value/OD Ratio
Negative Specimens	≤0.90
Equivocal Specimens	0.91 to 1.09
Positive Specimens	≥1.10

   a. An OD ratio ≤0.90 indicates no significant amount of IgM antibodies to rubella detected. A negative result indicates no current infection with rubella. However, specimens taken too early during a primary infection may not have detectable levels of IgM antibody. When health care professionals suspect a primary infection, another specimen should be obtained within seven days, and tested concurrently in the same assay with the original specimen, to look for seroconversion.
   b. An OD ratio ≥1.10 indicates that IgM antibodies specific to rubella were detected. A positive value indicates a primary or reactivated infection with rubella. Presume that such individuals are at risk of transmitting rubella infection but are not necessarily currently contagious.
   c. Specimens with OD ratio values in the equivocal range (0.91 - 1.09) should be retested in duplicate. Report any two of the three results which agree. Evaluate repeatedly equivocal using an alternate serological method and/or re-evaluate by drawing another sample one to three weeks later.

LIMITATIONS OF THE ASSAY

1. Results of the Anti-Rubella Virus IgM are not by themselves diagnostic. Interpret results in light of the patient's clinical condition and results of other diagnostic procedures.
2. Rubella virus specific IgG antibody may compete with IgM for binding sites and cause false negative results. Rheumatoid factor, if present along with specific IgG, will cause false positive results. The Sample Diluent contains an absorbent that will remove IgG from the test specimen and significantly reduces the possibility of false positive or false negative results.
3. Heterotypic IgM antibody responses may occur in patients infected with Epstein-Barr virus, and sera from patients with infectious mononucleosis may have false positive results in the rubella IgM ELISA (15).
4. Samples taken too early during the course of a primary infection may not have detectable levels of rubella specific IgM. A negative result does not rule out a primary infection with rubella virus.
5. The Anti-Rubella Virus IgM cannot distinguish the difference between vaccine-induced antibody and antibody resulting from a natural infection.
6. Patients with autoimmune disease may present with false positive anti-rubella IgM results.
7. The performance of the Anti-Rubella Virus IgM has not been validated using neonatal samples.

EXPECTED RESULTS

During a primary infection with rubella virus, IgM specific antibodies become detectable within two to five days after onset of rash (9). IgM specific antibodies remain detectable for one month but may persist for longer than 6 months in some patients (9).

sebia
The new language of life

PERFORMANCE CHARACTERISTICS

1. **Comparative Studies**

    The Anti-Rubella Virus IgM was compared to a commercially available Rubella IgM ELISA Test System for the detection of IgM antibodies to the rubella virus, using 229 serum samples obtained from two plasma centers in the Southeast and a reference laboratory. Also included were nine samples from a rubella virus vaccine. Both test systems evaluated all samples. A summary of the results follows in Table 1.

    Rubella Seroconversion Panel:

    Nine consecutive samples from a patient immunized with rubella virus vaccine were evaluated using the Anti-Rubella Virus IgM and the reference Rubella IgM ELISA test system. In addition, testing of each sample in the panel occurred using the Anti-Rubella Virus IgG. A summary of the results follows in Table 2. The Anti-Rubella Virus IgM identified the second bleed as positive, while the reference IgM ELISA identified the second bleed as equivocal. The third bleed was positive on both Rubella IgM assays. Rubella IgG positivity was not identified until the fourth bleed.

    Table 1: Anti-Rubella Virus IgM vs. Reference Rubella IgM ELISA

		Anti-Rubella Virus IgM			
		Positive	Negative	Equivocal*	Total
Reference Rubella IgM ELISA	Positive	33	0	0	33
	Negative	5	173	6	184
	Equivocal*	8	2	2	12
	Total	46	175	8	229

    *Calculations do not include the equivocal samples.

    Relative Sensitivity = 33/33 (100%)   Relative Specificity = 173/178 (97.2%)   Percent Agreement = 206/211 (98.6%)

    Table 2: Summary of Rubella Seroconversion Panel Reactivity

Sample ID	Bleed Date	ZEUS ELISA IgM	Commercial ELISA IgM	ZEUS ELISA IgG
SC1	11/30/90	0.214 (Negative)	Negative	0.114 (Negative)
SC2	12/05/90	1.862 (Positive)	Equivocal	0.195 (Negative)
SC3	12/07/90	1.857 (Positive)	Positive	0.835 (Negative)
SC4	12/12/90	2.610 (Positive)	Positive	1.441 (Positive)
SC5	12/14/90	1.983 (Positive)	Positive	1.384 (Positive)
SC6	12/19/90	1.494 (Positive)	Equivocal	1.823 (Positive)
SC7	12/21/90	1.324 (Positive)	Positive	2.052 (Positive)
SC8	12/26/90	1.104 (Positive)	Equivocal	2.295 (Positive)
SC9	12/28/90	0.780 (Negative)	Negative	1.785 (Positive)

2. **Precision and Reproducibility:**

    Five samples were tested to determine intra-assay and inter-assay variation. Samples were classified as follows: One - negative; Two – negative near equivocal zone; Three – equivocal; Four – high positive; and Six – low positive. On each of three days, each sample was tested once a day, eight times each, on each master lot. A responsible party then calculated the mean OD ratio and coefficient of variation from the resulting data. Depiction of the results of the experiment is below.

    Table 3: Summary of Variability Testing

	Lot A				Lot B				Lot C				Inter-Assay	
	Day One		Day Two		Day One		Day Two		Day One		Day Two			
Sample	Ratio	% CV	Ratio	% CV	Ratio	% CV	Ratio	% CV	Ratio	% CV	Ratio	% CV	Ratio	% CV
1	0.105	27	0.047	31	0.040	60	0.090	23	0.026	31	0.073	87	0.06	48
2	0.751	3.1	0.655	5.5	0.539	7.1	0.732	13.9	0.540	5.7	0.795	3.6	0.669	16.4
3	1.010	2.8	0.987	8.3	1.020	10.1	1.010	2.5	1.010	1.2	0.926	9.2	0.994	3.5
4	2.000	1.2	1.970	9.3	2.170	<0.1	2.160	9.1	2.030	11.3	1.870	3.4	2.033	5.7
5	1.520	2.1	1.290	3.2	1.390	7.3	1.360	5.4	1.340	9.6	1.280	5.1	1.347	4.1

3. **Cross Reactivity**

    Cross reactivity studies were performed to assess interference in the test procedure by rheumatoid factor (RF), EBV-IgM, and antibodies to nuclear antigens. Twenty-eight samples, positive for RF by latex agglutination (1:20 - 1:640), were tested using the Anti-Rubella Virus IgM. None of the 28 samples was positive. Two of the samples were equivocal on the Anti-Rubella Virus IgM; one of the

two samples was also equivocal on the comparison Rubella IgM ELISA. Eight of nine samples containing EBV-IgM antibodies (IFA titer range = 1:10 - 1:2560) were negative when tested with the Anti-Rubella Virus IgM. One EBV-IgM sample (1:5120) was positive. Forty-five of 46 ANA samples were negative when tested with the Anti-Rubella Virus IgM. One sample, exhibiting a homogeneous pattern (1:1280) and weak cytoplasmic staining (1:40) was positive. These studies indicate that interference with the test procedure by RF, EBV-IgM, and ANA are minimal.

REFERENCES

1. Cooper LZ: The history and medical consequences of rubella. Rev. Infect. Dis. 7:502-510, 1985.
2. Assad F, and Ljungars-Esteves K: Rubella - World impact. Rev. Infect. Dis. 7:529-536, 1985.
3. Cooper LZ, Greene RH, Krugman S, Giles JP, and Mirick GS: Neonatal thrombocytopenic purpura and other manifestations of rubella contracted *in utero*. Am. J. Dis. Child. 110:416-427, 1965.
4. Miller E, Cradock-Watson JE, and Pollock IM: Consequences of confirmed maternal rubella at successive stages of pregnancy. Lancet 2:782-784, 1982.
5. Hinman AR, Bart KJ, Orenstein WA, and Preblub SR: Rational strategy for rubella vaccination. Lancet 1:39-41, 1983.
6. Herrman KL: Rubella virus. In: Lennette EH, Balows A, Hausler WJ, and Shadomy HJ, eds. Manual of Clinical Microbiology, American Society for Microbiology, Washington, DC, pp.779-784, 1985.
7. Herrman KL: Available rubella serologic tests. Rev. Infect. Dis. 7:5108-5112, 1985.
8. Vaheri A, and Salonen EM: Evaluation of solid-phase enzyme immunoassay procedure in immunity surveys and diagnosis of rubella. J. Med. Virol. 5:171-181, 1980.
9. Enders G, Knotek F, and Pacher U: Comparison of various serological methods and diagnostic kits for the detection of acute, recent, and previous rubella infection, vaccination, and congenital infections. J. Med. Virol. 16:219-232, 1985.
10. Fraser KB, Shirodaria PV, and Stanford CF: Fluorescent staining and human IgM. Br. Med. J. 3:707, 1971.
11. Salonen EM, Vaheri A, Suni J, and Wager O: Rheumatoid factor in acute viral infections: Interference with determination of IgM, IgG, and IgA antibodies in enzyme immunoassay. J. Infect. Dis. 142:250-255, 1980.
12. Johnson RB, and Libby R: Separation of immunoglobulin M (IgM) essentially free of IgG from serum for use in systems requiring assay of IgM-type antibodies without interference from rheumatoid factor. J. Clin. Micro. 12:451-454, 1980.
13. Lennette DA: Collection and preparation of specimens for virological examination. in: EH Lennette, A Balows, WJ Hausler, and HJ Shadomy, eds. Manual of Clinical Microbiology, 4th ed. American Society for Microbiology, Washington, DC: ch 61, p 687-693, 1985.
14. Procedures for the Handling and Processing of Blood Specimens. NCCLS Document H-18, Approved Guideline.
15. Morgan-Capner P, Tedder RS, and Mace JE: Rubella-specific IgM reactivity in sera from cases of infectious mononucleosis. J. Hyg. (Camb) 90:407-413, 1983.
16. U.S. Department of Labor, Occupational Safety and Health Administration: Occupational Exposure to Bloodborne Pathogens, Final Rule. Fed. Register 56:64175-64182, 1991.
17. Procedures for the Handling and Processing of Blood Specimens for Common Laboratory Tests; Approved Guidelines – 4th Edition (2010). CLSI Document GP44-A4 (ISBN 1-56238-724-3). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, PA 19087.

sebia
The new language of life

GLOSSARY OF SYMBOLS

The following symbols **may** have been used in the labelling of this product or products associated with this product.

Symbol	Description	Symbol	Description
(Manufacturer symbol)	Manufacturer	(Keep away from sunlight symbol)	Keep away from sunlight
IVD	*In vitro* diagnostic medical device	PLATE	Plate
REF	Catalogue number	CONJ	Conjugate
Σ n	Sufficient for *n* tests	CTRL +	Positive Control
LOT	Batch code	CTRL –	Negative Control
(Use by symbol)	Use by	CAL	Calibrator
(Temperature limitation symbol)	Temperature limitation	DIL SPE	Sample Diluent
CONT	Contents	SOLN TMB	TMB
UDI	Unique Device Identifier	SOLN STOP	Stop Solution
(Warning triangle symbol)	Consult the warnings and precautions	WASH 10X	Wash Buffer Concentrate (10X)
(Consult instructions symbol)	Consult electronic instructions for use	EN	English
(Store upright symbol)	Store in the upright position	Made in the USA	Made in the USA
RX Only	Applicable for U.S.A: Prescription *in vitro* diagnostic product	(Corrosive symbol)	Corrosive
(Hazardous communication symbol)	Hazardous Communication		

sebia
The new language of life